Regadenoson

Generic Name: Regadenoson

Brand Names: Lexiscan, Rapiscan

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₈N_₈O_₅

CAS Number: 313348-27-5

Unique Ingredient Identifier: 7AXV542LZ4

Background: Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

Indication: Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Stress Echocardiography Study With Regadenoson

Phase 2

Terminated

Conditions: Heart Disease
Coronary Artery Disease

Interventions: Drug: regadenoson

First Posted Date: 2009-05-25

Last Posted Date: 2014-01-23

Lead Sponsor: Gilead Sciences

Target Recruit Count: 22

Registration Number: NCT00907764

Locations: 🇬🇧
Northwick Park Hospital, Harrow, United Kingdom

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson

Early Phase 1

Completed

Conditions: Ischemic Heart Disease

Interventions: Drug: Regadenoson

First Posted Date: 2009-04-15

Last Posted Date: 2012-04-10

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 50

Registration Number: NCT00881218

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Stress Testing and Cardiac Magnetic Resonance

Phase 4

Completed

Conditions: Coronary Disease

Interventions: Drug: regadenoson

First Posted Date: 2009-03-30

Last Posted Date: 2021-07-12

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT00871260

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

Phase 4

Completed

Conditions: Kidney Diseases
Coronary Artery Disease

Interventions: Drug: Placebo
Drug: Regadenoson

First Posted Date: 2009-03-18

Last Posted Date: 2012-05-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 511

Registration Number: NCT00863707

A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease

Phase 4

Completed

Conditions: Asthma
Coronary Artery Disease
Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: Regadenoson

First Posted Date: 2009-03-17

Last Posted Date: 2012-09-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 1009

Registration Number: NCT00862641

Effects of Body Mass Index on the Hyperemic Response to Regadenoson

Not Applicable

Completed

Conditions: Decreased Vascular Flow
Endothelial Dysfunction
Obesity

Interventions: Drug: Adenosine
Drug: Regadenoson

First Posted Date: 2009-03-11

Last Posted Date: 2011-05-24

Lead Sponsor: University of Utah

Target Recruit Count: 30

Registration Number: NCT00859833

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging

Not Applicable

Completed

Conditions: Coronary Disease

Interventions: Drug: regadenoson

First Posted Date: 2009-03-09

Last Posted Date: 2016-05-11

Lead Sponsor: University of Chicago

Target Recruit Count: 120

Registration Number: NCT00857792

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Regadenoson R-T Perfusion Imaging Trial

Phase 1

Completed

Conditions: Coronary Artery Disease
Myocardial Perfusion Abnormalities

Interventions: Drug: Regadenoson

First Posted Date: 2009-02-05

Last Posted Date: 2024-12-27

Lead Sponsor: University of Nebraska

Target Recruit Count: 100

Registration Number: NCT00837369

Locations: 🇺🇸
University of Nebraska Medicial Center, Omaha, Nebraska, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Phase 3

Completed

Conditions: Coronary Artery Disease (CAD)

Interventions: Drug: regadenoson
Radiation: technetium
Drug: overencapsulated caffeine
Drug: placebo

First Posted Date: 2009-01-22

Last Posted Date: 2024-12-03

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 347

Registration Number: NCT00826280

Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)

Early Phase 1

Terminated

Conditions: Coronary Artery Disease
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Angina

Interventions: Drug: Regadenoson
Drug: Dobutamine

First Posted Date: 2008-09-30

Last Posted Date: 2018-09-26

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 14

Registration Number: NCT00763035

Locations: 🇺🇸
WAKE FOREST UNIVERSITY Baptist Medical Center, Winston-Salem, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy